Pay in 4 interest-free payments of $7.38 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Study outcomes The primary outcome was major adverse cardiovascular events (MACE), defined as a composite of cardiovascular death, nonfatal myocardial infarction (MI), or nonfatal stroke, over a 4.5-year follow-up period, consistent with the SOUL trial
Was Losing Control of Obesity and Diabetes Centers for Disease Control and Prevention data shows: - Obesity prevalence crossed 43% heading into 2025 - Were projected to approach 50% by 2030 without intervention No healthcare system in the world can absorb that level of chronic disease burden
PubMed laboratory research record [PMID: 41680520] PubMed record related to this compound for laboratory literature review
Cardiovascular Protection : Studies have shown that GLP-1/GIP receptor agonists can reduce the risk of major cardiovascular events, including heart attack and stroke
US$ 28.71
US$ 29.18
US$ 21.50
US$ 23.02
US$ 23.46
